Index

aldosterone, 8–9
anemia, 2–3
anesthesia, 159
Cesarean section, 162–3
epidural anesthesia, 162–3
general anesthesia, 163
spinal anesthesia, 162
eclampsia management, 171
epidural, 159–60, 162–3
fluid management, 166–70
monitoring, 164–6
preoperative assessment, 160–2
cardiovascular system, 160–1
central nervous system, 161
coagulation cascade, 161–2
respiratory system, 160
small bolus of fluids, 160
angiogenic factors, 27
predictive value, 51–3, 53–6
angiotensin converting enzyme inhibitors, 91
angiotensin receptor blockers, 91
anti-angiotensin II receptor autoantibodies (AT1-AA), 29, 56–7
anticonvulsant therapy, 148–9, 153
antidiuretic hormone (ADH), 10–11
antihypertensive treatment, 153
chronic hypertension, 66–7, 69–71
eclampsia, 152–3
gestational hypertension, 86–91
severe preeclampsia, 131–2, 134–5
postpartum management, 137
antioxidants, 23–4, 71–2
aspirin, preeclampsia prevention, 71
asymmetric dimethyl arginine (ADMA), 57
atenolol, 88
autoantibodies, 29, 56–7
Barker hypothesis, 19
bed rest, 84
beta-blockers, 70, 86,
See also specific drugs
blood pressure, 14
eclampsia management, 152–3
invasive monitoring, 165–6
measurement, 113, 133–4
preoperative assessment, 160–1
regulation, 5–6
blood tests, 118–19
blood volume changes in pregnancy, 2
calcium-channel blockers, 70,
See also nifedipine
calcium, preeclampsia prevention, 72
cardiac output, 4–5
monitors, 170
cardiovascular changes in pregnancy, 4–9
blood pressure regulation, 5–6
cardiac output, 4–5
electrocardiogram, 15
endothelial function, 7–9
jugular venous pulse, 15
signs and symptoms of, 12
cardiovascular disease following preeclampsia mechanisms, 178–81
endothelial dysfunction, 179–80
inflammation, 181
metabolic syndrome and insulin resistance, 180–1
pregnancy as a stress test, 178–9
observational data, 176–8
central venous pressure (CVP), 169
Cesarean section, anesthesia, 162–3
epidural, 162–3
general, 163
spinal, 162
chest X-ray, 15
chronic hypertension, 38, 63–4,
See also hypertension in pregnancy
adverse pregnancy outcome, 64–5
antihypertensive treatment, 66–7, 69–71
first-line drugs, 69–70
second-line agents, 70–1
causes, 39
fetal assessment, 72–3
labor and delivery, 73
maternal evaluation, 65–6
place of treatment, 71
pre-pregnancy evaluation, 66–7
superimposed preeclampsia prevention, 71–2
treatment aims, 67–9
complicated and secondary hypertension, 68–9
mild to moderate hypertension, 67–8
severe hypertension, 69
coagulation, 23
preoperative assessment, 161–2
coupling factors, 3–4
coarctation of the aorta, 102
convulsions. See eclampsia
corticosteroids, 132
C-reactive protein (CRP), 181
creatinine, 11, 14, 41
protein:creatinine ratio (PCR), 41, 119–20
critical care unit admission, 171
cushing's syndrome, 104–5
cytokines, 28
delivery, 73, 85
eclampsia and, 151–2
sever preeclampsia and, 136
diazepam, 148
diuretics, 91
dyslipidemia, 24–5
eclampsia, 141
atypical, 153
cerebral imaging findings, 143
diagnosis, 146
diagnostic criteria, 146
differential diagnosis of seizures, 146
etiology, 142–3
convulsions, 142
fetal heart rate changes during a seizure, 150
incidence, 141–2
management, 146–53, 155
acute eclampsia, 147–8, 151
anesthesia, 171
blood pressure control, 152–3
delivery, 151–2
hospitalized patients, 149–51
multidisciplinary care, 171
prevention of recurrent convulsions, 148–9
rapid evaluation during or after a seizure, 147
maternal transport, 154
natural history, 143–5
outcomes, 150, 154–5
prevention, 154
prognosis, 145
seizure prediction, 145–6
electrocardiogram (ECG), 15

Index

endoglin, 27
soluble endoglin (sEng), 52–3, 54–5
endothelins (ET), 8
endothelium
dysfunction in preeclampsia, 21–2
later-life cardiovascular disease and, 179–80
role in cardiovascular system, 7–9
end-stage renal disease (ESRD), 177
epidural anesthesia
analgesia, 159–60
Cesarean section, 162–3
epigastric pain, 113
ergometrine, 73
fetal assessment, 72–3, 135
fetal growth restriction (FGR)
eutherapy, 131
fibromuscular dysplasia (FMD), 100
fluid management, 166–70
central venous pressure (CVP), 168–9
clinical examination, 168
hourly urine output, 168
interventions for low output, 169
monitoring intervention response, 168
pulmonary arterial catheterization, 169
renal, 166
respiratory, 166–7, 168
triggers for intervention, 167
flurosemide, 91
free fatty acids (FFAs), 25
furosemide, 137
general anesthesia, 163
genetic factors, 29–30
gestational hypertension (GH), 35–6, 37, 79, 91, See also hypertension in pregnancy
etiology and pathogenesis, 81–2
evaluation, 82–3
management, 83–4
bed rest, 84
delivery timing, 85
hospitalization, 84
pharmacological therapy, 85, 86–91
preadrenal glucocorticoids, 85
salt restriction, 84
natural history, 80
outcomes, 80–1
glomerular filtration rate (GFR), 10
glucocorticoids, antenatal, 85
glycosuria, 14
hematological changes in pregnancy, 1–4
blood volume, 2
couagulation factors, 3–4
hematological indices, 2–3
headache, 112
heart sounds, 13–14
hospitalization, 84, 114, 118
admission criteria, 172–3
level 1 care, 172
level 2 care, 173
level 3 care, 173
eclampsia management, 149–51
hot flushes, 13
hourly urine output, 168
interventions for low output, 169–70
hydralazine, 90, 135, 153
hypertension in pregnancy, 35,
See also chronic hypertension;
gestational hypertension (GH);
preeclampsia; secondary hypertension
classification, 35–6
diagnosis, 36–7
long-term significance, 175
pathophysiology of hypertension, 19–20
postnatal management, 42–3
hyperventilation, 12
Index

inflammation, 22–3, 28
later-life cardiovascular disease and, 181
insulin resistance, 24
later-life cardiovascular disease and, 180–1
invasive blood pressure monitoring, 165–6
jugular venous pulse, 15
kidney
anatomical changes in pregnancy, 9–10
physiological changes in pregnancy, 10–11
renal disease, 101–2
renal fluid management, 166
labetalol, 70, 86–8, 134–5, 137, 153
levels of care, 172
admission criteria, 172–3
level 1 care, 172
level 2 care, 173
level 3 care, 173
lipid peroxides, 27–8
liver function tests, 119
low density lipoproteins (LDLs), 24–5
magnesium sulfate, 131, 135, 136, 148
prevention of recurrent convulsions, 148–9
metabolic syndrome, 180–1
methylxypate, 69–70, 89–90
migraine, 112
multidisciplinary care, 171
nasal congestion, 13
neutrophil activation, 22–3
nifedipine, 70, 88–9, 134–5, 137
nitric oxide (NO), 8
nocturia, 10
edema, 13
pulmonary, 166–7, 168
admission to critical care unit, 170–1
oligohydramnios, 135
oxidative stress, 23–4
oxprenolol, 88
pheochromocytoma, 103
physiological anemia, 2–3
physiological hydrourer of pregnancy, 9–10
placental fragments, 28–9
placental growth factor (PIGF), 54–5
placental protein 13 (PP-13), 50–1
plasma sodium concentration, 11
plasma volume changes in pregnancy, 2
platelet activation, 23
postnatal management, 73–4
follow-up, 42–3
postpartum hypertension, 42
preeclampsia, 38, 45–7, 109, 125,
See also hypertension in pregnancy
etiology, 25–30
angiogenic factors, 27
autoantibodies, 29
genetics, 29–30
inflammation and cytokines, 28
lipid peroxides, 27–8
placental fragments and microparticles, 28–9
uteroplacental pathology, 25–7
anesthesia in. See anesthesia complications, 128
diagnosis, 40–1, 111–12
severe preeclampsia, 126
features of, 21–5
dyslipidemia, 24–5
endothelial dysfunction, 21–2
insulin resistance, 24
oxidative stress, 23–4
systemic inflammation and coagulation, 22–3
incidence, 125–7
later-life cardiovascular disease relationship, 176–8
mechanisms, 178–81
management strategy, 114–22
allocation to named consultant, 120
blood tests, 118–19
hospital admission, 118
hospital step-up assessment, 115–18
incorporation into local policy and practice, 122
medical review, 120
patient involvement, 121–2
protein:creatinine ratio (PCR) assessment, 119–20
thresholds for further action, 114–15
umbilical artery Doppler assessment, 119
monitoring, 120–1
outcomes, 126, 128
pathogenic model, 30–1
postnatal management, 42–3, 73–4
prediction of, 41–2, 46–7, 58
serum markers, 50–7
uterine artery Doppler velocimetry, 47–50
prevention with chronic hypertension, 71–2
risk factors, 40
assessment of, 110–11
early referral and, 111
severe preeclampsia management, 128–9, 131–6, 137–8
before 25 weeks' gestation, 130–1
expectant management with FGR, 131
indications for immediate delivery, 134
mode of delivery, 136
multidisciplinary care, 171
observational and retrospective studies, 130
postpartum management, 137
recommendations, 131–6
summary of published results, 129–30
severity, 125
symptoms, 112–13
pregnancy. See also hypertension in pregnancy
as a stress test, 178–9
cardiovascular changes, 4–9, 12
blood pressure regulation, 5–6
cardiac output, 4–5
electrocardiogram, 15
endothelial function, 7–9
jugular venous pulse, 15
hematological changes, 1–4
blood volume, 2
coaulation factors, 3–4
hematological indices, 2–3
renal changes, 9–12, 14
anatomical changes, 9–10
physiological changes, 10–11
protein excretion, 12
primary hyperaldosteronism, 104
propranolol, 70
protein:creatinine ratio (PCR), 41, 119
protein excretion, 12
proteinuria, 40–1
estimation, 113–14
pulmonary arterial catheterisation, 169
pulmonary edema, 166–7, 168
admission to critical care unit, 171
relaxin, 8
renal blood flow (RBF), 10
renal changes in pregnancy, 9–12, 14
anatomical changes, 9–10
fluid management, 166
physiological changes, 10–11
protein excretion, 12
signs and symptoms of, 12
renal disease, 101–2
renin, 11
renovascular disease, 100
salt restriction, 84
screening, 46–7
serum markers, 50–7
uterine artery Doppler velocimetry, 47–50
secondary hypertension, 97–8,
See also hypertension in pregnancy
clinical findings, 99
endocrine system causes, 103–5
Cushing’s syndrome, 104–5
pheochromocytoma, 103
primary hyperaldo-steronism, 104
renal system causes, 100–2
vascular system causes, 102
seizures. See eclampsia
serum markers, 50–7
angiogenic factors, 51–3, 53–6
placental protein 50, 51
soluble endoglin (sEng), 52–3, 54–5
soluble fms–like tyrosine kinase–1 (sFlt-1), 27, 52–3
predictive value, 53–5, 56
spinal anesthesia, 162
supine hypotensive syndrome, 6, 14
sweating, 13
thiazide diuretic, 70–1
thromboxane, 7–8
tumor necrosis factor-alpha (TNFa), 28
umbilical artery Doppler assessment, 119
ureteric dilatation, 9–10
urinary frequency, 10
uterine artery Doppler velocimetry, 47–50
uteroplacental pathology, 25–7
varicosities, 13
vascular endothelial growth factor (VEGF), 52, 56
vascular stress test, 20–1
venous thromboembolism, 74
vitamin C, 23–4, 71–2
vitamin E, 23–4, 71–2